Renowned Cleveland Clinic cardiologist and lead author of the landmark SELECT trial joins Canary to advance CCT-217 into Phase 1...
Novel siRNA Therapeutic Demonstrates Significant Fat Loss and Remarkable Lean Body Mass Preservation, and Promises Superior Adherence New York, NY,...
CCT-217 Demonstrates Significant Weight Loss and Preserves Lean Body Mass with Potential for Single or Twice-Yearly Dosing Abstract According to...
CCT-217 Demonstrates Significant Weight Loss and Preserves Lean Body Mass with Potential for Single or Twice-Yearly Dosing New York, November...
First-in-Class Gene-Targeted Approach to Promote Fat-Burning, Preserve Lean Body Mass, and Enhance Metabolic Health by Harnessing the Endocannabinoid System
Canary Global has been accepted into Canada’s SR&ED program which aims to encourage R&D work conducted for the advancement of...
Pioneering RNA Therapy
We are revolutionizing healthcare by harnessing the power of cutting-edge RNA therapies to develop and deliver innovative treatments that addresses the root causes of diseases. We are committed to fostering a culture of scientific excellence and collaboration to create life-changing treatments that are safe, effective, and accessible to all.